Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 16;7(4):ofaa095.
doi: 10.1093/ofid/ofaa095. eCollection 2020 Apr.

Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy

Daniel S Fierer  1 , David L Wyles  2
Affiliations

Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy

Daniel S Fierer et al. Open Forum Infect Dis. .

Abstract

Background: Direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) result in initial cure rates of 95% to 99% and re-treatment cure rates of 95%. Nevertheless, given the sheer magnitude of infected persons, some will ultimately fail multiple DAA therapies, and re-treatment of these persons has not been adequately studied.

Methods: We evaluated treated an HIV-infected man with cirrhosis from genotype 1b HCV who had failed 3 DAA regimens.

Results: We treated and cured our "particularly difficult-to-cure" patient with sofosbuvir plus glecaprevir/pibrentasvir plus ribavirin for 24 weeks. We discuss the literature on potential biological factors behind his treatment failures such as lack of HCV seroconversion during his infection course, and multiple failures of hepatitis B seroconversion after vaccination, and the rationale for choosing his curative salvage regimen.

Discussion: There are no clinical trials-proven re-treatment regimens for "particularly difficult-to-cure" patients. Multiple patient- and virus-related factors that do not affect cure rates in treatment-naive patients may need to be considered in choosing a re-treatment regimen for these patients. These regimens may need to include combinations drugs that are not available in single-tablet form, addition of ribavirin, and longer durations of treatment than standard.

Keywords: HIV infection; cirrhosis; complex DAA failure; particularly difficult to cure.

PubMed Disclaimer

References

    1. Edlin BR, Eckhardt BJ, Shu MA, et al. . Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62:1353–63. - PMC - PubMed
    1. Feld JJ, Jacobson IM, Hézode C, et al. . ASTRAL-1 Investigators Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599–607. - PubMed
    1. Wyles D, Bräu N, Kottilil S, et al. . ASTRAL-5 Investigators Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis 2017; 65:6–12. - PMC - PubMed
    1. D’Ambrosio R, Pasulo L, Puoti M, et al. . NAVIGATORE-Lombardia Study Group Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol 2019; 70:379–87. - PubMed
    1. Bourlière M, Gordon SC, Flamm SL, et al. . POLARIS-1 and POLARIS-4 Investigators Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376:2134–46. - PubMed